• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    35839452.pdf
    Size:
    692.3Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Elsawy, M.
    Chavez, J. C.
    Avivi, I.
    Larouche, J. F.
    Wannesson, L.
    Cwynarski, K.
    Osman, K.
    Davison, K.
    Rudzki, J. D.
    Dahiya, S.
    Dorritie, K. A.
    Jaglowski, S. M.
    Radford, John A
    Morschhauser, F.
    Cunningham, D.
    Martin Garcia-Sancho, A.
    Tzachanis, D.
    Ulrickson, M. L.
    Karmali, R.
    Kekre, N.
    Thieblemont, C.
    Enblad, G.
    Dreger, P.
    Malladi, R.
    Joshi, N.
    Wang, W. J.
    Solem, C. T.
    Snider, J. T.
    Cheng, P.
    To, C.
    Kersten, M. J.
    Show allShow less
    Affiliation
    Queen Elizabeth II Health Sciences Centre, Canada
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Here we report the first comparative analysis of patient-reported outcomes (PROs) with chimeric antigen receptor T-cell therapy versus standard-of-care (SOC) therapy in second-line relapsed/refractory large B-cell lymphoma (R/R LBCL) from the pivotal randomized phase 3 ZUMA-7 (NCT03391466) study of axicabtagene ciloleucel (axi-cel) versus SOC. PRO instruments were administered at baseline, day 50, day 100, day 150, month 9, and every 3 months from randomization until 24 months or an event-free survival event. The quality of life (QoL) analysis set comprised patients with a baseline and ≥1 follow-up PRO completion. Prespecified hypotheses for QLQ-C30 Physical Functioning, Global Health Status/QoL, and EQ-5D-5L visual analogue scale (VAS) were tested using mixed-effect models with repeated measures. Clinically meaningful changes were defined as 10 points for QLQ-C30 and 7 for EQ-5D-5L VAS. Among 359 patients, 296 (165 axi-cel, 131 SOC) met inclusion criteria for QoL analysis. At day 100, statistically significant and clinically meaningful differences in mean change of scores from baseline were observed favoring axi-cel over SOC for QLQ-C30 Global Health Status/QoL (estimated difference 18.1 [95% CI, 12.3-23.9]), Physical Functioning (13.1 [95% CI, 8.0-18.2]), and EQ-5D-5L VAS (13.7 [95% CI, 8.5-18.8]; P<.0001 for all). At day 150, scores significantly favored axi-cel versus SOC for Global Health Status/QoL (9.8 [95% CI, 2.6-17.0]; P=.0124) and EQ-5D-5L VAS (11.3 [95% CI, 5.4-17.1]; P=.0004). Axi-cel showed clinically meaningful improvements in QoL over SOC. Superior clinical outcomes and favorable patient experience with axi-cel should help inform treatment choices in second-line R/R LBCL.
    Citation
    Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood. 2022 Jul 15. PubMed PMID: 35839452. Epub 2022/07/16. eng.
    Journal
    Blood
    URI
    http://hdl.handle.net/10541/625430
    DOI
    10.1182/blood.2022015478
    PubMed ID
    35839452
    Additional Links
    https://dx.doi.org/10.1182/blood.2022015478
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1182/blood.2022015478
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Quality-Adjusted Time Without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel Versus Standard of Care in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Q-TWiST analysis of axi-cel versus standard of care.
    • Authors: Kersten MJ, Qiao Y, Shah R, Solem C, Snider JT, To C, Cheng P, Spooner C, Perales MA
    • Issue date: 2023 Jan 13
    • Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium.
    • Authors: Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin Y, Dahiya S, Lunning M, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Sehgal AR, Goy A, Hill BT, Vu K, Andreadis C, Munoz J, Westin J, Chavez JC, Cashen A, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL
    • Issue date: 2020 Sep 20
    • The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial.
    • Authors: Perales MA, Kuruvilla J, Snider JT, Vadgama S, Blissett R, El-Moustaid F, Smith NJ, Patel AR, Johnston PB
    • Issue date: 2022 Nov
    • Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
    • Authors: Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei MG, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR
    • Issue date: 2022 Nov 10
    • Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.
    • Authors: Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Ghobadi A, Rapoport AP, McGuirk J, Pagel JM, Muñoz J, Farooq U, van Meerten T, Reagan PM, Sureda A, Flinn IW, Vandenberghe P, Song KW, Dickinson M, Minnema MC, Riedell PA, Leslie LA, Chaganti S, Yang Y, Filosto S, Shah J, Schupp M, To C, Cheng P, Gordon LI, Westin JR, All ZUMA-7 Investigators and Contributing Kite Members
    • Issue date: 2022 Feb 17
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.